Pharmaceuticals

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

* Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C lowering * Robust and sustainable treatment effects support at least bi-annual dosing regimen * Best-in-class potential of novel PC...

2024-11-18 09:00 2093

Boehringer Ingelheim Commits to Veeva Vault CRM

Top biopharma company selects the next generation of CRM for life sciences as its commercial foundation for future expansion and launches SINGAPORE, Nov. 18, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Boehringer Ingelheim is the latest global to...

2024-11-18 09:00 1265

Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA

ROCKVILLE, Md. and SUZHOU, China, Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that a New Drug Applica...

2024-11-17 22:24 1739

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease

* IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program  * ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) * The planned clinical ...

2024-11-15 20:00 1346

Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2024-11-15 09:55 1366

SEKISUI Completes £15.7 Million Expansion in cGMP Biopharma CDMO Capacity

Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products BURLINGTON, Mass., Nov. 15, 2024 /PRNewswire/ -- SEKISUI Diagnostics' microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGM...

2024-11-14 23:45 952

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.

PISCATAWAY, N.J., Nov. 13, 2024 /PRNewswire/ -- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading sc...

2024-11-13 23:51 1108

Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies

BRADENTON, Fla. and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell reprogramming, immune modulation, and drug delivery, is excited to announce its official launch. The com...

2024-11-13 20:30 1380

Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology

MELBOURNE, Australia and BERLIN, Germany, Nov. 13, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and licence agreement withBerlin -based Eckert & Ziegler SE (EZAG) for the use of EZAG's cyclotro...

2024-11-13 16:18 1632

Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum's Disease Treatment

- CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease treatment. - CBL-514 received both FDA Orphan Drug Designation and Fast Track designation for Dercum's disease treatment earlier this year. - CBL-514 Phase 2 study for Dercum's disease showed that it c...

2024-11-13 13:36 1261

Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing

* Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. * Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug P...

2024-11-12 21:15 1474

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III c...

2024-11-12 19:30 1574

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

* After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. * The pharmacokinetic profile supports a once-daily oral dosing regimen for GZR18 tablets. * The safety and tolerability of G...

2024-11-12 19:00 1295

Tsingke Successfully Showcases Innovations at BIO-Europe 2024

BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke proudly concluded its participation in BIO-Europe 2024, held fromNovember 4 to 6 inStockholm, Sweden. As one of the premier global events for the biotechnology, pharmaceutical, and investment sectors, over 5,500 attendees ...

2024-11-12 17:07 1011

World's First Patent Acquired for Animal Supplement "Pinfenon" (S) (R)

- Patent Covers Invention of Treatment Drug and Prophylactic Drug for Lowering Cardiac Disorder Markers in Dogs as Well as Their Manufacturing Methods - TOKYO, Nov. 12, 2024 /PRNewswire/ -- Scarecrow Incorporated, based in Tokyo's Shibuya Ward, is pleased to announce that it has acquired the worl...

2024-11-12 14:00 1394

Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.

Acquisition Strengthens Lakeside's Pharmaceutical Logistics Capabilities in China, Projected to Add US$7 Million in Annual Revenue ITASCA, Ill., Nov. 11, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain s...

2024-11-11 21:45 1682

Economist Impact's 4th edition Future of Health Asia to empower healthcare stakeholders by building strategies for a sustainable healthcare system, and igniting investment for an inclusive and healthier future

Members of the media are invited to register here . SINGAPORE, Nov. 11, 2024 /PRNewswire/ -- The 4th edition Future of Health A...

2024-11-11 20:56 1863

Diabetes Singapore and GSK Join Forces to Spotlight Increased Risk of Viral Infections for People with Diabetes

* Diabetes Singapore and GSK aim to enhance awareness and improve lives affected by diabetes through educational talks and activities on World Diabetes Day * 1 in 3 people will get shingles in their lifetime; People with diabetes are 38% more likely to contract shingles[1] * People with dia...

2024-11-11 20:47 1396

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

Highlights: * Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis * Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulat...

2024-11-11 20:30 1162

ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults

* Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0....

2024-11-11 19:36 1334
1 ... 11121314151617 ... 320